Reading GEVO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GEVO free→Reading GEVO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GEVO free→
NASDAQMaterialsSpecialty ChemicalsSnapshot 2026-06-16
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak. Earnings quality cannot be assessed since the company is unprofitable. Management's recent track record has been unsteady, with frequent changes. Risk is elevated, and the sector backdrop is a headwind. Compared with sector peers, GEVO is below typical. Peer multiples imply a price about 90% below where it trades (it looks expensive on this basis); the read is expensive, growth-justified. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 1 valuation methods, at three horizons. Current price $1.45. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $1.43 GEVO trades at 3× p/s — 1.9× the 1× p/s peer median. The market is re-rating it beyond its own range; our $0.74 fair value is medium-confidence here. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 94% near-term growth, in line with our forecast of about 100%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only expensive valuation — not the full expensive x weak x turbulent stack. Regime (Crisis) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Materials names rated weak grew net income 51% of the time over the next year (vs 59% for the rest of the cohort, n=1088).
Over the trailing year it converted 0.31x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
13 material management or governance events in the past 24 months, led by M&A activity. Historically, Materials names rated volatile grew net income 61% of the time over the next year (vs 51% for the rest of the cohort, n=235).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.02 → $-0.02 (+0.5% / 30d). 1 raised, 1 cut, 3 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 50% of analysts rate Buy.
1 PT revisions / 30d. Avg target 17.1% above current price.
Transition story with positive analyst positioning (often a turnaround setup).
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$213.
How much price usually moves either way.
On a bad day, this stock has moved -$670.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,955.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: A big change in management score may show a better company direction or plan.
Confirms:Management score increases by more than 5 points in the next earnings report.
Disproves:Management score decreases or stays the same in the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for GEVO yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
No upside scenarios in the latest snapshot.
No downside scenarios in the latest snapshot.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 7, 2026, Gevo, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the three months ended March 31, 2026. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Specialty Chemicals.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
GEVO Gevo, Inc. | Below typical Show detailsSector percentile: 16 of 100 | expensive | elevated |
SHW Sherwin-Williams | Typical Show detailsSector percentile: 66 of 100 | full | moderate |
ECL Ecolab | Above typical Show detailsSector percentile: 83 of 100 | expensive | moderate |
PPG PPG Industries | Above typical Show detailsSector percentile: 90 of 100 | fair | moderate |
LYB LyondellBasell | Typical Show detailsSector percentile: 55 of 100 | — | moderate |
Not investment advice. As of 2026-06-16.
via XLB
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Targeting a run-rate annualized $40 million of Adjusted EBITDA by the end of 2026.
Stated in 2 of last 2 quarters. Revenue was $42.9M in 2026-Q1, down from $45.3M in 2025-Q4. Despite the revenue decline, management continues to target a $40M Adjusted EBITDA run-rate by year end. Persistent statement, limited substantive delivery this quarter.
“We target achieving a run-rate annualized $40 million of Adjusted EBITDA by the end of this year.”
“The Company reaffirms its near-term target of reaching run rate Non-GAAP Adjusted EBITDA of approximately $40 million per year.”
Aiming for neutral to positive cash flow from operations for the fiscal year 2026.
Newly stated in 2025-Q4. Cash from operating activities was -$21.1M in 2026-Q1, indicating a significant gap to the neutral to positive cash flow target. Limited progress towards this goal so far.
Why it matters: Growth in revenue for the materials sector may mean recovery, which helps Gevo.
Confirms:Sector revenue growth turns positive from the current near -1 percent.
Disproves:Sector revenue growth is still going down or is still negative.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) Compensatory Arrangements of Certain Officers. As previously disclosed, Patrick R. Gruber retired as the Chief Executive Officer of Gevo, Inc., a Delaware corporation (the “Company”), on April 1, 2026. Following Dr. Gruber’s retirement, the Company entered into a Consulting Services Agreement (the “Consulting Agreement”) with Patrick Gruber LLC…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 11, 2026, Angelo Amorelli informed the Board of Directors (the “Board”) of Gevo, Inc. (the “Company”) that he will not stand for re-election to the Board at the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Dr. Amorelli will continue to serve as a member of the Board until the expiration of his term at the Annual Me…
Results of Operations and Financial Condition. On March 5, 2026, Gevo, Inc. (the “Company”) issued a press release announcing the Company’s financial results for year ended December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this
Entry into a Material Definitive Agreement. On February 6, 2026 (the “ Effective Date ”), Gevo, Inc. (the “ Company ”), through direct and indirect subsidiaries, completed a refinance transaction with entities affiliated with Orion Infrastructure Capital. The refinance transaction included entering into an Amendment (as defined below) to the Existing Credit Agreement (as defined below), which permitted and financed the redemption of the Bonds (as defined below) issued for the benefit of the R…
“We are now targeting neutral to positive cash flow from operations for 2026.”